Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteomic patterns associated with response to breast cancer neoadjuvant treatment.
Shenoy A, Belugali Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I, Balint N, Bossel N, Pavlovsky A, Barshack I, Kaufman B, Agami R, Yarden Y, Dadiani M, Geiger T. Shenoy A, et al. Among authors: yarden y. Mol Syst Biol. 2020 Sep;16(9):e9443. doi: 10.15252/msb.20209443. Mol Syst Biol. 2020. PMID: 32960509 Free PMC article.
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors.
Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Børresen-Dale AL, Pilpel Y, Yakhini Z, Segal E, Yarden Y. Avraham R, et al. Among authors: yarden y. Sci Signal. 2010 Jun 1;3(124):ra43. doi: 10.1126/scisignal.2000876. Sci Signal. 2010. PMID: 20516477
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, Pikarsky E, Paz-Ares L, Yarden Y. Romaniello D, et al. Among authors: yarden y. Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394. Cancers (Basel). 2020. PMID: 32847130 Free PMC article.
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.
Canu V, Donzelli S, Sacconi A, Lo Sardo F, Pulito C, Bossel N, Di Benedetto A, Muti P, Botti C, Domany E, Bicciato S, Strano S, Yarden Y, Blandino G. Canu V, et al. Among authors: yarden y. Cell Death Differ. 2021 May;28(5):1493-1511. doi: 10.1038/s41418-020-00677-9. Epub 2020 Nov 23. Cell Death Differ. 2021. PMID: 33230261 Free PMC article.
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, Lev S, Geiger T, Ciechanover A, Ulitsky I, Seger R, Ruppin E, Yarden Y. Nataraj NB, et al. Among authors: yarden y. Cell Rep. 2022 Feb 22;38(8):110418. doi: 10.1016/j.celrep.2022.110418. Cell Rep. 2022. PMID: 35196484 Free PMC article.
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. Noronha A, et al. Among authors: yarden y. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. Cancer Discov. 2022. PMID: 35895872 Free PMC article.
351 results